Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06996301 · ClinicalTrials.gov registry record · NA

Clinical Utility of a PCR Compared to Culture and Sensitivity Testing for the Management of cUTI in Adults.

A NA study of Urinary Tract Infection (Diagnosis) and Urinary Tract Infection Complicated, sponsored by Doc Lab.

Completed
Registry status
NA
Development phase
773
Enrollment target
6
Study locations

NCT06996301 is a NA study of Urinary Tract Infection (Diagnosis) and Urinary Tract Infection Complicated that has completed, run by Doc Lab. The registered enrollment target is 773 participants, above the 224-participant average among 4 other Urinary Tract Infection (Diagnosis) trials with a reported enrollment target (245% higher). The trial reports 6 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06996301, a NA study of Urinary Tract Infection (Diagnosis) and Urinary Tract Infection Complicated, has completed, sponsored by Doc Lab.

COMPLETED
Registry status
NA
Development phase
773 participants
Enrollment target
6
Study locations

Study Summary

Complicated urinary tract infections (cUTIs) often lead to the overuse of empiric antibiotics, risking inappropriate treatment and contributing to antimicrobial resistance. This randomized, multi-center, investigator-blinded clinical trial is the first global head-to-head comparison of molecular diagnostic testing (Polymerase Chain Reaction : PCR) versus conventional culture and sensitivity (C\&S) for managing cUTIs in adults. Conducted across six U.S. clinical sites, the study aimed to evaluate the clinical utility of PCR-guided treatment relative to C\&S-guided care. Eligible adult patients were randomized 1:1 into two diagnostic arms-PCR or C\&S-after providing informed consent. Urine samples were collected before randomization, tested by both methods, but clinicians remained blinded to the comparator results to avoid bias. Treatment decisions were based only on the assigned test results. Urine was collected at baseline (Day 1) and at end-of-study (Day 28). Samples were processed centrally: the PCR method (DocLab UTM 2.0) detected 28 uropathogens and 16 antibiotic resistance gene classes; C\&S testing quantified bacterial loads and assessed antimicrobial susceptibility using standard thresholds (≥10⁵ CFU/mL). The primary endpoint was the number of patients in each arm achieving a Favorable Clinical Outcome (FCl) at Day 28, defined as either: * Clinical Cure (complete symptom resolution requiring no further antibiotics), or * Clinical Improvement (partial symptom resolution without new symptoms or IV antibiotics). Secondary endpoints included: * Microbiological eradication at EOS (via C\&S and PCR). * Clinician satisfaction with diagnostic usefulness and result clarity. * Turnaround time comparison between PCR and C\&S. * Concordance analysis of test results between PCR and C\&S. * FCl rates in discordant cases, where PCR and C\&S results disagreed.

Interventions

  • DIAGNOSTIC_TEST Treatment guided by the PCR results
  • DIAGNOSTIC_TEST Treatment guided by the C&S results

Study Locations (6)

Georgia

  • Albany Urology Clinic & Surgery Center - Albany
  • Augusta Urology Associates - Evans
  • Colquitt Regional Medical Center - Moultrie

California

  • Silicon Valley Medical Development - San Jose

Missouri

  • Phoenix Urology of St Joseph - Saint Joseph

Oklahoma

  • Norman Urology Associates - Norman

Trial Details

FieldValue
Enrollment Target 773 participants
Start Date 2023-07-31
Est. Completion 2024-05-31
Phase NA

Sponsor

Doc Lab

1 total trials

What the Registry Record Tells You About NCT06996301

The ClinicalTrials.gov registry entry for NCT06996301 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 773 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 224-participant average among 4 other Urinary Tract Infection (Diagnosis) trials with a reported enrollment target (245% higher). The listed sponsor is Doc Lab, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Urinary Tract Infection (Diagnosis) appearing as the primary indexed condition, and to 2 interventions - of which Treatment guided by the PCR results is the first listed.

NCT06996301 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Georgia, California, Missouri.

Frequently Asked Questions

What is clinical trial NCT06996301 about?

NCT06996301 is a clinical study titled "Clinical Utility of a PCR Compared to Culture and Sensitivity Testing for the Management of cUTI in Adults.". Complicated urinary tract infections (cUTIs) often lead to the overuse of empiric antibiotics, risking inappropriate treatment and contributing to antimicrobial resistance. This randomized, multi-center, investigator-blinded clinical trial is the first global head-to-head comparison of molecular dia...

What is the current status of trial NCT06996301?

This trial is currently completed. It is a NA study. The enrollment target is 773 participants. The study started on 2023-07-31. Estimated completion is 2024-05-31.

What conditions does trial NCT06996301 study?

This clinical trial studies the following conditions: Urinary Tract Infection (Diagnosis), Urinary Tract Infection Complicated, Urinary Tract Infection (cUTI).

What interventions are being tested in trial NCT06996301?

The interventions under investigation include: Treatment guided by the PCR results (DIAGNOSTIC_TEST), Treatment guided by the C&S results (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06996301?

This trial is sponsored by Doc Lab, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06996301 being conducted?

This trial has 6 study locations across California, Georgia, Missouri, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Urinary Tract Infection (Diagnosis)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.